David V. Goeddel, PhD
InvestorPartner Emeritus at The Column Group
Find your path to David
28 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.
Tim KutzkeyunlockedDavid: together at The Column Group
×11David: together at The Column Group
About
David V. Goeddel led creation of the first marketed recombinant therapeutics (including insulin and growth hormone), and built Tularik to IPO and sale to Amgen, with a rare scientist-CEO perspective.
Invests in
BiotechHealthtech
Colleagues at The Column Group
Aadit Shah
Principal at The Column Group
Arnav Mehta, MD, PhD
Venture Partner at The Column Group
Carla Daniel
Partner at The Column Group
Craig Parker
Venture Partner at The Column Group
David Goeddel
Managing Partner at The Column Group
David V. Goeddel, Ph.D.
General Partner at The Column Group
Hui Tian
Partner at The Column Group
Hui Tian, PhD
Partner at The Column Group
Frequently asked questions
- Who is David V. Goeddel, PhD?
- David V. Goeddel led creation of the first marketed recombinant therapeutics (including insulin and growth hormone), and built Tularik to IPO and sale to Amgen, with a rare scientist-CEO perspective.
- Where does David V. Goeddel, PhD work?
- David V. Goeddel, PhD is Partner Emeritus at The Column Group.
- What does David V. Goeddel, PhD invest in?
- David V. Goeddel, PhD invests in Biotech, Healthtech.